Rankings
▼
Calendar
CYTK
Cytokinetics, Incorporated
$8B
Q3 2016 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$59M
Gross Profit
$41M
69.7% margin
Operating Income
$32M
55.0% margin
Net Income
$33M
56.5% margin
EPS (Diluted)
$0.74
QoQ Revenue Growth
+917.7%
Cash Flow
Operating Cash Flow
-$12M
Free Cash Flow
-$12M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$158M
Total Liabilities
$75M
Stockholders' Equity
$83M
Cash & Equivalents
$30M
← FY 2016
All Quarters
Q4 2016 →
CYTK Q3 2016 Earnings — Cytokinetics, Incorporated Revenue & Financial Results | Market Cap Arena
